Ovodefensins are a novel beta defensin-related family of antimicrobial peptides containing conserved glycine and six cysteine residues. Originally thought to be restricted to the albumen-producing region of the avian oviduct, expression was found in chicken, turkey, duck, and zebra finch in large quantities in many parts of the oviduct, but this varied between species and between gene forms in the same species. Using new search strategies, the ovodefensin family now has 35 members, including reptiles, but no representatives outside birds and reptiles have been found. Analysis of their evolution shows that ovodefensins divide into six groups based on the intra-cysteine amino acid spacing, representing a unique mechanism alongside traditional evolution of sequence. The groups have been used to base a nomenclature for the family. Antimicrobial activity for three ovodefensins from chicken and duck was confirmed against Escherichia coli and a pathogenic E. coli strain as well as a Gram-positive organism, Staphylococcus aureus, for the first time. However, activity varied greatly between peptides, with Gallus gallus OvoDA1 being the most potent, suggesting a link with the different structures. Expression of Gallus gallus OvoDA1 (gallin) in the oviduct was increased by estrogen and progesterone and in the reproductive state. Overall, the results support the hypothesis that ovodefensins evolved to protect the egg, but they are not necessarily restricted to the egg white. Therefore, divergent motif structure and sequence present an interesting area of research for antimicrobial peptide design and understanding protection of the cleidoic egg.
INTRODUCTION
The avian egg has many mechanisms in place to protect itself from bacterial invasion, as does the reproductive tract; these can effectively be considered as either physical or chemical [1] . An important part of the egg's chemical defense is provided by antimicrobial peptides, otherwise known as host defense peptides. A particular group of these, the ovodefensins, was recently shown to be a new family of egg-specific defensins [2] . The family had been shown to be conserved across divergent avian species and was thought to be avian specific [2] . Proteomic methods had confirmed the presence of the chicken, turkey, and duck members of the ovodefensin family in the egg [3] [4] [5] , and quantitative reverse transcriptase PCR confirmed that the expression of the chicken member gallin was restricted to the oviduct of the hen [2] . In contrast, classical defensins are widely distributed across many tissues and can be found in all vertebrates [6] . Currently, only three of the classical chicken defensins are found in the egg: AvBD9, 10, and 11 [7] . It has yet to be determined if the expression of other avian members of the ovodefensin family are also restricted to the oviduct, which would imply that the whole family is likely to be expressed principally for inclusion in the egg. If this is the case, ovodefensins are likely to be influenced by gonadal steroids and would be expected to show expression patterns in response to steroids typical of egg-specific genes, such as ovalbumin [8] , and ''transiently expressed in neural precursors'' (TENP) [9] . Although the connection had not previously been made with classical vertebrate defensins, ovodefensins were classed as a new branch of this family largely because of the conservation of a characteristic sixcysteine sequence motif and a common glycine residue between C1 and C2 attributed to all vertebrate b-defensins [2] . Their position in the genome was also close to the bdefensin cluster on chromosome 3 [2] . The ovodefensins differ from classical vertebrate defensins in the spacing of amino acids within the six-cysteine sequence motif and are slightly shorter in length, the mature peptides ranging from only 39 to 41 amino acids, although they are still highly cationic, as is expected with defensins. Two cysteine sequence motifs were observed in ovodefensins, C-X5-C-X3-C-X11-C-X3-CC and C-X3-C-X3-C-X11-C-X4-CC [2] , which may be due to the fact that antimicrobial peptides are often under high selective pressure to evolve due to the ongoing arms race between pathogen and host, such as observed in classical vertebrate bdefensins [10] . Interestingly, the 3D structure of the chicken ovodefensin gallin has recently been solved, confirming the presence of the three-stranded antiparallel b-sheet observed in all classical b-defensins and reinforcing its relationship with the b-defensins [7] . However, gallin contains an additional short two-stranded b-sheet [7] ; this five-stranded arrangement supports the hypothesis that gallin and presumably the other ovodefensins form a structurally distinct subfamily of bdefensins.
Host defense peptides such as the defensins have been suggested previously as an interesting template for new classes of antimicrobial drugs, as they often possess a wide spectrum of antimicrobial activity [11, 12] . Cationic host defense peptides are small, typically containing a high abundance of positively charged and hydrophobic residues [13] . Gallin, the chicken representative of the ovodefensin family, was shown to be highly antibacterial against a laboratory-adapted strain of Escherichia coli [2] . It has since been suggested that its direct antimicrobial actions are limited to E. coli [7] ; however, few studies have been carried out relating to the antimicrobial capabilities of gallin and indeed this novel family of defensins.
Our overall aim of this study was therefore to determine the extent of the ovodefensin family using the possibility that evolution acting on spacing as well as sequence may reveal the presence of further molecules with novel cysteine sequence motifs; to determine if ovodefensins are avian specific, as was previously speculated; and to determine if ovodefensins are restricted to the oviduct and are therefore egg specific, as was the case with gallin. Finally, we wished to determine the antibacterial capabilities of gallin, a newly discovered chicken ovodefensin member (OvoDB1), and duck BPS 2 and the pH and salt sensitivity of gallin.
MATERIALS AND METHODS

Discovery of New Ovodefensin Family Members
Available genome databases Ensembl [14] , PreEnsembl [15] , and UCSC [16] were searched using TBLASTN and BlastP [17] to locate potential homologs using the 41-amino-acid mature peptide sequence of gallin (GenBank accession no. CBE70283.1) and the previously published 39-amino-acid mature peptide sequence of taeniopygin 2 [2] . Further iterative searches were made with the homologs discovered. Protein database Uni-prot [18] was also searched using BlastP to identify peptide sequences previously unidentified as ovodefensins.
Phylogenetic Analysis of the Evolution of Spacing Between Conserved Residues
A distance matrix based on the amino acid sequence length between each cysteine and the conserved glycine residue was built with the statistical computing software R [19] for all known and newly discovered ovodefensins (Supplemental Table S1 ; Supplemental Data are available online at www. biolreprod.org). Hierarchical clustering for each distance matrix was calculated using R [19] , which was then used to produce a cladogram of the phylogenetic relationships using the R ''hclust'' function (Fig. 1A) . Similarly cladograms based on spacing were produced separately for avian species (Fig. 1C) and reptiles (Fig. 1D) . The resulting ovodefensin ''subfamilies'' were used to propose new nomenclature for existing and newly discovered ovodefensin molecules ( Table 1) that currently have trivial names based on a range of criteria determined by the discoverer. We propose that each gene has the prefix ''OvoD'' to identify it as an ovodefensin and is attributed a letter from ''A'' to ''F'' to identify the subfamily to which it belongs. Within a subfamily, each gene is given a numerical identifier allowing multiple forms of the same gene to be identified. For example, gallin would become Gallus gallus OvoDA1 and the additional copies OvoDA1_2 and OvoDA1_3. Through the use of this nomenclature, meleagrin is Meleagris gallopavo OvoDA1, allowing it to be easily identified as a member of the same subfamily and a gallin ortholog, aiding comparison across species. This nomenclature will be used throughout the remainder of this article to aid clarity.
In addition to this, a phylogram was constructed using Mega5 [20] and the core peptide sequence from the conserved glycine until the fourth cysteine residue inclusively for sequences where the number of amino acids within this region was identical (Fig. 1B) . Mega5 was also used to construct phylograms based on the whole mature peptide sequences for OvoDA family members (Fig.  1E ) and also OvoDB (Fig. 1F) .
ClustalW alignments of each of the six cysteine sequence motifs (OvoDAOvoDF) and a global alignment of all ovodefensin peptides can be found in Supplemental Figure S1 .
Animals and Tissue Collection
To determine G. gallus OvoDA1 and OvoDB1expression, the following tissues were taken from four sexually mature White Leghorn LSL hens (Lohmann): oviduct (magnum, isthmus, shell gland vagina), ovarian stroma, crop, duodenal loop, gizzard, caeca, cloaca, lung, adrenals, cerebellum, retina, spleen, liver, kidney, and heart.
For analysis of Anas platyrhynchos OvoDB1 (dBPS 1 ) and OvoDA1 (dBPS 2 ) expression, tissues were collected from three sexually mature Pekin ducks (Cherry Valley): oviduct (magnum, isthmus, shell gland, vagina), ovarian stroma, crop, proventriculus, small intestine, duodenal loop, gizzard, large intestine, caeca, cloaca, gallbladder, lung, trachea, pituitary, adrenals, cerebellum, hypothalamus, tongue, spleen, breast muscle, liver, kidney, and heart.
Combined expression of M. gallopavo OvoDA1 (Meleagrin) and OvoDA2 and expression of OvoDB1 was determined using tissues from four sexually mature turkeys: Oviduct (magnum, isthmus, shell gland, vagina), ovarian stroma, esophagus, crop, duodenal loop, gizzard, caeca, cloaca, lung, adrenals, cerebellum, tongue, spleen, breast muscle, skin, liver, kidney and heart.
Taeniopygia guttata OvoDA1 (Taeniopygin 1) and OvoDB1 (Taeniopygin 2) expression was measured using five adult female zebra finches courtesy of Dr. Karen Spencer, University of St. Andrews, Scotland: oviduct (magnum, isthmus shell gland), ovarian stroma, small intestine, duodenal loop, gizzard, lung, spleen, breast muscle, skin, liver, kidney, and heart.
After dissection, all tissue was placed in RNA later (Ambion) and stored at 48C overnight before storage at À808C. Samples weighed no more than 100 mg.
Time of Oviposition
Magnum tissue was obtained from sexually mature White Leghorn hens with an ovum at various positions in the oviduct (see Gong et al. [2] for details). Briefly, magnum tissue was collected either when the egg was in the magnum (n ¼ 5), in the shell gland where the stage of calcification was determined by electron microscopy and recorded as early (n ¼ 8), mid-(n ¼ 9), and late (n ¼ 10) calcification, or during a pause day (n ¼ 11) when there was no evidence of ovulation.
Effect of Oviduct Development
To determine if G. gallus OvoDA1 (gallin) and G. gallus OvoDB1 expression differed between in-lay hens (n ¼ 11) and those where the oviduct had regressed due to incubation behavior (n ¼ 11), magnum and shell gland tissue were collected from hens of a Silkie 3 White Leghorn cross (see Whenham et al. [9] ). After dissection, tissue was frozen in liquid N 2 and stored at À808C. Samples weighed no more than 100 mg.
Induction with Steroid Hormones
The protocol for examining induction of G. gallus OvoDA1 (gallin) with steroid hormones was adapted from a method described by Kunnas et al. [21] . Three-week-old ISA brown chicks (n ¼ 60) were given an intramuscular injection of 0.5 mg diethylstilbestrol (DES; Sigma-Aldrich D4268) in 0.5 ml propylene glycol (vehicle) daily for 7 days (primary stimulation) and then split into two groups. Ten days following the primary DES treatment, one group of birds (n ¼ 30) were restimulated on two consecutive days with DES (primed group), and another group of birds (nonprimed; n ¼ 30) received vehicle. The next day within both groups, a subset were given a single intramuscular injection of progesterone (Sigma-Aldrich P3972; 20 mg/kg; n ¼ 10), estradiol (Sigma-Aldrich E8515; 10 mg/kg; n ¼ 10), or vehicle (propylene glycol; 1 ml/ kg; n ¼ 10). All chicks were killed 12-16 hours after the single injection; magnum tissue was removed and immediately frozen in liquid N 2 and then stored at À808C.
All animals were killed in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986, United Kingdom, under project license PPL 60/3964. All procedures were approved by the Roslin Institute's ethics committee.
RNA Preparation
Tissues were homogenized in Ultraspec II total RNA isolation reagent (AMS Biotechnology) using an Ultraturrax homogenizer (IKA-Werke GmbH & Co. KG). Samples were then processed as per the manufacturer's protocol.
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RT-PCR Transcript Detection and Sequencing Characterization
One-microgram samples of chicken, duck, turkey, and zebra finch magnum RNA were reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer's protocol. Primers (Table 2) were designed to ensure complete coverage of each ovodefensin's coding sequence. PCR amplification was performed using the following conditions: an initial denaturation at 958C for 4 min, followed by 40 cycles of 30 sec at 958C, 30 sec at 588C, and 30 sec at 728C, followed by an extension of 7 min at 728C. All products were separated by 2% agarose-gel electrophoresis and visualized using SYBR Safe DNA gel stain (Invitrogen).
The amplified PCR fragments were sequenced with their respective forward and reverse primers. Sequences were assembled by Staden [22] to produce consensus sequences.
Rapid amplification of cDNA ends (RACE) was carried out using a 5 0 /3 0 RACE second-generation kit (Roche Diagnostics) to determine the number of exons encoding G. gallus OvoDA1 (gallin). Briefly, for 5 0 RACE, synthesis of first-strand cDNA was carried out on magnum RNA using primer gallinSP1 and the mRNA template degraded. The cDNA was purified using a High Pure PCR Product Purification kit (Roche Diagnostics) and poly (A) tailed at the 3 0 end. The tailed cDNA was amplified by PCR using the oligo (dt)-anchor primer provided and a further nested primer OvoDA1SP2. The product from this PCR was run using 3% agarose-gel electrophoresis and visualized using SYBR Safe DNA gel stain (Invitrogen). PCR product was excised from the gel and cleaned from the agarose using a QIAEX II Gel Extraction Kit (Qiagen) and sequenced using primer OvoDA1SP2. 3 0 RACE used the oligo (dT)-anchor primer to initiate cDNA synthesis at the poly (A) tail of magnum RNA. Amplification using a PCR anchor primer and OvoDA1SP5 was then performed directly. PCR product was excised from the gel and cleaned from the agarose using a QIAEX II Gel Extraction Kit (Qiagen) and sequenced using primer OvoDA1 SP5. Primer sequences for RACE can be found in Table 2 .
Reverse Transcription Quantitative PCR
A first-strand cDNA synthesis kit (GE Healthcare Life Sciences) was used for reverse transcription of a 0.5-lg sample of total RNA as per the manufacturer's instructions. Reverse-transcribed samples were diluted by a factor of 10 with H 2 O prior to use. Primer3 [23] was used to design primers for quantification; sequences can be found in Table 2 . RT-quantitative PCR (qPCR) was carried out with 8 ll of the diluted cDNA and a primer concentration of 20 mM according to Agilent Brilliant III SYBR Green qPCR master mix (Agilent) instructions. The following conditions were used for RTqPCR; 958C for 2 min, then 40 cycles of 958C for 15 sec and 608C for 30 sec using an MX3000 (Stratagene). Reactions containing no template were run as a control. Standard PCR conditions were used to obtain products for the construction of a standard curve, and Lamin B-receptor (LBR) expression was measured in the same way to normalize concentrations (as described previously) [9] in order to determine the absolute concentration of the different ovodefensin transcripts. Products were run on an agarose gel to confirm that only products of the correct length with no primer-dimer were amplified as well as to ensure that there was only a single peak dissociation curve; correct amplification was also confirmed through sequencing of the PCR product.
Production and Titers of Polyclonal Antibodies
Production of antibodies was carried out by Dundee Cell Products Ltd; epitopes for raising antibodies were chosen on the basis of their surface probability, hydrophilicity, and antigenicity with consideration of the peptide solubility. Briefly, two rabbits per peptide were immunized four times at 3-wk intervals by intramuscular injection of synthesized G. gallus OvoDB1 (R108 and R109) epitope (CNKKDEWSFHQ) and T. guttata OvoDB1 (R112 and R113) epitope (KGEREEHTED) synthesized by Dundee Cell Products Ltd and emulsified in Freunds adjuvant. Serum was collected after each immunization. Antiserum was purified via a two-step affinity purification using cognate peptides coupled to beads.
To measure the titers of anti-G. gallus OvoDB1 and anti-T. guttata OvoDB1 in their respective antisera, the synthesized epitopes were diluted with 50 mM Na 2 CO 3 (pH 9.6) to a final concentration of 1 ng/ll (0.5 ng/ll of each epitope), and 50 ll of the solution were added to each well of a 96-well plate. The plate was covered and stored overnight at 48C. This was aspirated, and the wells were incubated for 2 h at room temperature with 200 ll tris-buffered saline (pH 7.5), 0.5% Tween 20 (TBST), and 1% bovine serum albumin (BSA) to block unsaturated binding sites. Preimmune (null) sera and antisera were serially diluted 1/1000-1/32 000 with TBST, 1% BSA, pH 7.5. To each well, 10 ll of diluted null sera or antisera were added, and the plate was incubated for 2 h at room temperature. The plate was washed five times with TBST. Horseradish peroxidase-conjugated anti-rabbit IgG (SAPU) diluted 1/2000 with TBST, 1% BSA, pH 7.5; 100 ll were applied to each well, and the plate was incubated at room temperature for 2 h. After five washings with TBST, peroxidase activity was detected by adding 100 ll detection solution (100 mM citric acid, 200 mM Na 2 HPO 4 , O-phenylenediamine, H 2 O 2 ). The reaction was stopped with 50 ll of 2 M H 2 SO 4 and absorbance (490 nm) measured spectrophotometrically.
Immunohistochemistry
Wax-embedded tissues were sectioned at 3 microns using a Thermoshandon finesse microtome, lifted onto Vectabond slides (Vector Laboratories), and incubated at 608C for 1 h before they were dewaxed and taken down to water. Heat-induced epitope retrieval was carried out using a Menarini Access Retrieval Unit in buffer (sodium citrate, pH 6) for 1 min and 40 sec at 1258C full pressure. Each section was then loaded onto a DAKO Autostainer. A standard IHC protocol was then applied; optimal staining was achieved at a 1:500 dilution for the polyclonal anti-T. guttata OvoDB1 (113_KGE _2.1) and 1:1000 for the anti-Gallus gallus OvoDB1 (108 CNK-1.3). The sections were viewed using a Leica DM 4000 B microscope and images captured using a Leica DC480 camera with Qwin program for PC. 
Peptide Production
Gallus gallus OvoDA1 and OvoDB1 and A. platyrhynchos OvoDA1 were commercially obtained from Almac Group (East Lothian, Scotland). The peptides were synthesized on a 0.2-mmol scale using an automated Applied Biosystems 433 peptide synthesizer and fluorenylmethoxy (Fmoc) solid-phase peptide synthesis protocols. Each amino acid was coupled after activation with diisopropylcarbodiimide/Oxyma pure. On completion of the synthesis, the peptide was cleaved from the resin, and the side chain protecting groups were removed using a cocktail of trifluoroacetic acid, ethanedithiol tri-isopropylsilane, and H 2 O. The peptide was folded in the presence of oxidized and reduced glutathione at pH 8 and the final product isolated using preparative HPLC and a gradient of H 2 O, acetonitrile, and 0.1% trifluoroacetic acid. Freeze-dried peptides were reconstituted in 10% dimethyl sulfoxide (DMSO).
Antimicrobial Activity Assay
The antimicrobial assay, adapted from methods described previously [2, 24, 25] , was used to determine the efficacy of G. gallus OvoDA1 and OvoDB1 and A. platyrhynchos OvoDB1. Five different strains were used to assess antimicrobial activity: E. coli K-12 strain DH5a, avian pathogenic E. coli (APEC) O78:H9 strain v7122, Salmonella enterica serovars Enteritidis (SE125109) and Typhimurium (ST4/74), and Staphylococcus aureus (8325-4). Escherichia coli DH5a and S. aureus 8325-4 are nonpathogenic laboratory strains of bacteria, and APEC, SE125109, and ST4/74 are pathogenic strains with a known ability to colonize chickens. Bacteria were cultured overnight at 378C in Luria broth (LB) or tryptone soya broth (TSB) (S. aureus); 250 ll of overnight culture were subcultured into 20 ml of LB or TSB and incubated at 378C for 3 h. After the second incubation, 20 ll of culture were diluted with 2 ml of PBS, pH 7.4. Ten microliters of G. gallus OvoDA1 and OvoDB1 or A. platyrhynchos OvoDB1 peptide (3, 6, 15, 30, 60, 150 , 300, and 600 lM) or DMSO (control) or PBS were added to 50 ll of diluted culture to produce final concentrations of 0.5, 1, 2.5, 5, 10, 25, 50, and 100 lM, respectively. For S. aureus, final concentrations of 10, 25, 50, 100, 150, and 200 lM were used. After vortexing, this was incubated at 378C for 3 h, and then the suspensions were serially diluted to 1 3 10 À4 with PBS; all dilutions were plated on LB or tryptone soya agar plates. Plates were incubated overnight at 378C, and the colonies were counted. Results are expressed as a reduction in colony-forming units per milliliter (CFU/ml), and, where possible, the effective dose 50 (ED50) was calculated using the DRC program in R [26] .
Effect of pH and Salt on Antimicrobial Activity
The antimicrobial assay as outlined above (2.9.1) was adapted to test the effect of pH on the efficacy of G. gallus OvoDA1 against E. coli DH5a. The assay was carried out as before but using PBS at pH 6.4, 7.4, and 8. 4 . Gallus gallus OvoDA1 was tested at final concentrations of 1.9, 5.6, 16.7, and 50 lM. The antimicrobial assay (2.9.1) was adapted to test the effect of salt sensitivity on G. gallus OvoDA1 efficacy. PBS with NaCl concentrations of 50, 100, and 150 mM, pH 6.4, was used.
Sequencing and Database Submission
All sequencing was carried out by GATC biotech, and consensus sequences were submitted to EMBL, G. gallus OvoDB1 (EMBL accession no. LN717248), M. gallopavo OvoDB1 (EMBL accession no. LN717250), T. guttata OvoDA1 (EMBL accession no. LN717251), OvoDA1_2 (EMBL accession no. LN717252), and OvoDB1 (EMBL accession no. LN717253). Putative budgerigar, medium ground finch, anole lizard, American alligator, collared flycatcher, painted turtle, and Chinese soft-shelled turtle sequences were not submitted because they remain predicted but can be found in the supplementary data (Supplemental Table S1 ).
Statistical Analysis
One-way or two-way ANOVA and least significant difference to test between the means were used as appropriate for statistical analysis using Genstat (13th ed., VSN International Ltd). Log-transformed data were used where appropriate to equalize the variance.
RESULTS
Bioinformatic Analysis and Transcript Confirmation
TBLASTN similarity searches of available genomes located 24 new ovodefensin homologs (Supplemental Table S1 and Table 3 ). Hierarchical clustering based on the distance between each cysteine identifies six specific subfamilies termed OvoDA-OvoDF (Fig. 1A) . In the chicken, the first representative of OvoDB, a cysteine sequence motif with a shorter spacing between C1 and C2 and a longer spacing between C4 and C5 (C-X3-C-X3-C-X11-C-X4-CC), was identified on chromosome 3, where OvoDA1 (C-X5-C-X3-C-X11-C-X3-CC) and the classical chicken beta defensins are also located. This was named OvoDB1 in accordance with the proposed nomenclature outlined in 2.1.2 (Fig. 1, A and C, and Table 3 ). The first turkey representative of the OvoDB1 motif (Fig. 1, A and C, and Table 3 ) was discovered on chromosome 2, the same chromosome as M. gallopavo OvoDA1 (meleagrin). A further potential paralog of M. gallopavo OvoDA1 was also located on this chromosome; the mature peptide sequence shares a 95% identity with OvoDA1 and was named M. gallopavo OvoDA2 (Fig. 1, A and C, and Table 3 ). A budgerigar representative of subfamily B, Melopsittacus undulatus OvoDB1 (Fig. 1, A and C, and Table 3 ), was discovered during this analysis; however, a representative from the same subfamily (A) as gallin has yet to be located for this species. Three putative copies of a subfamily A ovodefensin were found in the April 2012 assembly of the medium ground finch genome: Geospiza fortis OvoDA1, OvoDA1_2, and OvoDA1_3 (Fig. 1 , A and C, and Table 3 ). A search of the flycatcher genome discovered a member from both the A and the B subfamilies; these were named Ficedula albicollis OvoDA1 and OvoDB1, respectively (Fig. 1, A and C, and Table 3 ). For the first time, reptile representatives of the ovodefensin family were identified. Two copies of Pelodiscus sinensis OvoDB1 (Fig. 1, A and D, and Table 3) were identified in the Chinese soft-shell turtle genome. In the painted turtle genome, a subfamily B member was also located: Chrysemys picta bellii OvoDB1 (Fig. 1, A and D, and Table 3 ). In addition to this, a new cysteine spacing motif (C-X3-C-X3-C-X13-C-X3-CC), which we have termed subfamily C, was uncovered. Within this, the painted turtle subfamily C contains two copies of the OvoDC1 gene and an OvoDC2 gene (Fig. 1 , A and D, and Table 3 ). TBLASTN searches of the American alligator genome identified two members of yet another new cysteine sequence motif: subfamily D (C-X3-C-X3-C-X11-C-X3-CC) and Alligator mississippiensis OvoDD1 and OvoDD2 (Fig. 1, A and D, and Table 3 ). Finally, two further motifs were uncovered in the anole lizard genome: subfamily E (C-X6-C-X3-C-X11-C-X2-CC) and F (C-X6-C-X4-C-X11-C-X2-CC).
Within subfamily E, one copy of Anolis carolinensis OvoDE1 was located, as were three copies of OvoDE2 and one copy of OvoDE3 (Fig. 1, A and D, and Table 3 ). One copy of each of the subfamily F members was identified: OvoDF1, OvoDF2, and OvoDF3 (Fig. 1, A and D, and Table 3 ). Genome build and chromosome/scaffold locations for each ovodefensin are outlined in Tables 1 and 3 .
Three homologs not previously classified as ovodefensins were also identified during this study. Shapiro et al. [27] produced a rock pigeon reference genome from which a putative subfamily A member was identified. This had been named cygnin due to its homology with black swan cygnin; we now propose the name Columba livia OvoDA1 (Fig. 1, A and C, and Table 3) . From this genome, a putative subfamily B member, named small basic protein, was also located, and the name C. livia OvoDB1 (Fig. 1, A and C, and Table 3 ) is proposed for this ovodefensin homolog. In addition to this TEWP, a loggerhead turtle peptide was isolated from egg white and shown to be a defensin [28] ; this peptide has the motif of a subfamily B ovodefensin, and we therefore suggest the name Caretta caretta OvoDB1 (Fig. 1, A and C, and Table 3 ).
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0 /3 0 RACE 5 0 /3 0 RACE using magnum RNA and primers resulted in a PCR product with 100% identity to the published G. gallus OvoDA1 (gallin) sequence (ENSGALG00000028311.1), the 5 0 and 3 0 sequence of which was derived by prediction. Alignment with the chicken genome confirmed that G. gallus OvoDA1 is encoded for by two exons.
Tissue Expression
Gallus gallus OvoDB1 expression was restricted to magnum and isthmus as previously documented with OvoDA1 (Fig. 2) . In contrast to this, both A. platyrhynchos OvoDA1 and OvoDB1 expression was greatest in the shell gland, although some expression was observed in both the magnum and the isthmus (Fig. 2) , and no expression was detected outside of the oviduct (data not shown). The combined expression of M. gallopavo OvoDA1 and OvoDA1_2 and expression of OvoDB1 was high across all oviduct tissues; the greatest expression for these turkey ovodefensins was measured in the shell gland, magnum, Expression of ovodefensin mRNA in a range of adult chicken (n ¼ 4), turkey (n ¼ 4), duck (n ¼ 3), and zebra finch (n ¼ 5) tissues measured by RTqPCR (mean 6 SEM). Expression was corrected for chicken, turkey, duck, or zebra finch LBR expression to normalize for any differences between tissues. Note: To accommodate the large differences in expression, the data are presented on the log scale.
and isthmus (Fig. 2) . Taeniopygia guttata OvoDA1 and OvoDB1 expression was also restricted to the oviduct, expression being observed most highly in the shell gland for both genes (Fig. 2) . It should be noted that vagina tissue was not available for the zebra finch. For all the ovodefensin transcripts analyzed, no expression was detected in tissues outside the reproductive tract (data not shown).
There was no significant effect of the position of the egg in the oviduct or the lack of an egg in the oviduct on G. gallus OvoDB1 expression in the magnum ( Fig. 3 ; ANOVA ¼ P ¼ 0.269). The level of G. gallus OvoDA1 and OvoDB1 expression in the magnum was higher (P , 0.001) in birds in-lay than in those with an oviduct in the regressed state (Fig.  4) . When estrogen and progesterone were administered to juvenile hens, G. gallus OvoDA1 expression (Fig. 5 ) was higher in birds treated with the two steroids (P , 0.001), and where priming with an estrogenic compound had been performed, overall expression increased (P , 0.001).
Immunohistochemistry
The chicken anti-OvoDB1 antiserum (108 CNK-1.3) produced positive staining in the tubular gland cells of the magnum (Fig. 6, A and C) . The ciliated and nonciliated cells lining the magnum region of the oviduct did not react to the primary antibody. No staining was observed in the isthmus, shell gland, or caecum (data not shown). In contrast to this, the zebra finch anti-OvoDB1 antiserum (113_KGE _2.1) produced positive staining in the tubular gland cells and surface epithelium of the magnum, isthmus, and shell gland (Fig. 7 , A, C, and E). No convincing staining was observed in the breast muscle (Fig. 7G) .
Antimicrobial Activity
Gallus gallus OvoDA1 (gallin) peptide achieved a relatively large effect on E. coli DH5a with around a 98% reduction in CFU/ml at 100 lM (Fig. 8A and Table 4 ); this is comparable to the results reported previously with BL21 [2] . Gallus gallus OvoDA1 achieved around a 40% reduction in viability of avian pathogenic E. coli O78:H9 strain v7122 when used at 50 or 100 lM (Fig. 8A and Table 4 ) and a .90% reduction in viability against S. aureus 8325-4, a Gram-positive organism, when used at 100 or 200 lM (Fig. 8B and Table 4 ). No reduction was observed against either of the Salmonella strains used in this study (data not shown). A 35% reduction in viability of E. coli DH5a was achieved with 100 lM G. gallus OvoDB1 (Table 4) , and a very small reduction was observed in APEC numbers (;3%). No reduction was observed against S. aureus, the Salmonella strains tested (data not shown). A duck representative of the ovodefensin family, A. platyrhynchos OvoDB1 (dBPS 2 ), showed a .80% reduction in viability of E. coli DH5a (Table 4 ), but no convincing activity was seen against any of the other strains tested.
Gallus gallus OvoDA1 potency as measured by ED50 did not differ significantly due to pH (P ¼ 0.42); the ED50 (6SEM) of G. gallus OvoDA1 at pH 6.4, 7.4, and 8.4 was 7.38 lM (615.3), 3.57 lM (61.4), and 3.67 lM (60.96), respectively (Fig. 9A) . The potency of G. gallus OvoDA1 at the ED50 level was also not affected by salt concentration (P ¼ 0.49); the ED50 of G. gallus OvoDA1 at 50, 100, and 150 mM NaCl was 3.55 lM (62.39), 3.88 lM (629.8), and 3.27 lM FIG. 3 . Expression of G. gallus OvoDB1 mRNA in magnum tissue at different stages of egg formation measured by RT-qPCR (n ¼ 8, mean 6 SEM). Gallus gallus OvoDB1 expression was corrected for LBR expression. Pause represents a day when the hen did not ovulate, so no egg is present. Magnum represents tissue taken when an egg is present in the magnum, and early, mid-, and late describes the stage of shell formation in the shell gland and indicates that the egg was not in the magnum when the sample was taken. ANOVA, P ¼ 0.269. FIG. 4 . Expression of G. gallus OvoDA1 (A) and G. gallus OvoDB1 (B) in magnum tissue of laying (L) and out-of-lay (NL) birds measured by RT-qPCR (n ¼ 11, mean 6 SEM). Nonlaying hens were those where the oviduct had regressed due to the withdrawal of gonadotrophic support with the onset of incubation behavior. Expression was corrected using LBR gene expression. Note the large difference in the Y-axis scale between A and B. Significance between laying state is indicated at P , 0.001 (***).
OVIDUCT OVODEFENSIN EVOLUTION (614.9), respectively (Fig. 9B) . However, at higher concentrations of G. gallus OvoDA1, the maximum antibacterial activity appeared to be diminished by higher salt concentration (Fig. 9B ).
DISCUSSION
Seven ovodefensins had previously been identified within divergent avian species, and it had been observed that two cysteine sequence motifs exist [2] , suggesting within the ovodefensins that there may be further divisions in structure and function (Table 1) . This study identified a further 25 ovodefensin members (Table 3 ) through genome analysis and attributed a further three previously known sequences to the group, expanding the ovodefensin family to include reptile species for the first time. It was first suggested by Gong et al. [2] that the ovodefensins appeared to be a new family of defensin molecules, most likely belonging to the b-defensin group. However, it was predicted that ovodefensins share the genomic organization of mammalian b-defensins, being encoded for by two exons [2] rather than the four exons that encode for classical avian defensins [6] . This study confirmed the exon arrangement of G. gallus OvoDA1 by defining the transcription start site, thus confirming the two-exon predictions. Where available, predictions of the newly discovered avian and reptilian ovodefensins also support the two-exon arrangement. In addition to an altered exon arrangement, the ovodefensins differ from classical avian defensins in the spacing within the cysteine sequence motif. When the 3D structure and specific cysteine pairing was solved by Hervé et al. [7] , it was observed that Gallus gallus OvoDA1 (gallin) had the classical disulfide pairing (C1-C5, C2-C4, C3-C6) of bdefensins. It was, however, demonstrated that G. gallus OvoDA1 contained an additional two-stranded parallel b-sheet compared to known beta-defensin structures and no aminoterminal helix; it is therefore possible that the ovodefensins form a new structural subfamily of defensins. Now phylogenetic analysis of both the spacing and the sequence of the ovodefensins suggests that multiple subfamilies may exist within the family (Fig. 1, A, C, and D) . These subfamilies include four new ovodefensin-like motifs-OvoDC (C-X3-C-X3-C-X13-C-X3-CC), OvoDD (C-X3-C-X3-C-X11-C-X3-CC), OvoDE (C-X6-C-X3-C-X11-C-X2-CC), and OvoDF (C-X6-C-X4-C-X11-C-X2-CC)-revealing that the ovodefensin family is much more diverse than was first thought. All four new cysteine spacing motifs appear to be reptile specific (Fig.  1, A and D) , whereas of the originally identified motifs, OvoDA (C-X5-C-X3-C-X11-C-X3-CC) was avian specific (Fig. 1, A and C) , and OvoDB (C-X3-C-X3-C-X11-C-X4-C) contained both avian and reptilian counterparts (Fig. 1, A, C,  and D) .
Phylogenetic analysis of spacing (Fig. 1A) suggests that a common ancestor gave rise to two progenitor molecules that appear in turn to have independently evolved three cysteine sequence motifs. However, if viewed in the context of sequence analysis (Fig. 1B) , it would appear that the OvoDB cysteine sequence motif has in fact evolved separately within both avian and reptilian lineages, suggesting that spacing is an important feature of the ovodefensin molecules. In a sense, this seems like a form of convergent evolution, albeit the available repertoire of spacing is relatively limited. In order to assess all the ovodefensin molecules together, either spacing (Fig. 1A) or a core region (Fig. 1B) was used; however, we recognize that this may influence the outcome of analysis, depending on the evolutionary constraints of each selection. In particular, analysis based on the core region of the molecule (Fig. 1B) produced some unexpected outliers; for example, within the OvoDA cluster, we see that the turkey molecules appear closer to the duck and swan than the chicken. However, when the fulllength peptides of the OvoDA subfamily are analyzed separately (Fig. 1E) , a more classical species arrangement is observed. This demonstrates the complex nature of what appears to be the coevolution of sequence and spacing and the need for both aspects to be studied in combination. Overall, the evolution within birds-and now in this study within another egg laying clade, the reptiles-of a large repertoire of peptides that vary not only in sequence but also in the spacing between conserved cysteine residues suggests that the spacing between these cysteine residues may be critical for function. The region between the first and second cysteine, which varies from three to six amino acids in length, for example, has been demonstrated in G. gallus OvoDA1 to be important because of the basic residue in an otherwise hydrophobic region [7] . Interestingly, the spacing between the third and fourth cysteine residues is constant (X11) in each ovodefensin subfamily with the exception of OvoDC, which has 13 residues in this region. Spacing between all cysteine residues is quite variable between ovodefensin subfamilies; indeed, it forms the basis of the proposed nomenclature. However, it should be noted that as this is an otherwise unvarying region and OvoDC has so far been identified only in reptiles, we may be observing a distinct ovodefensin-like family of peptides. It has been difficult to find examples in the literature of situations where the amino acid distance between conserved residues of a motif are altering or under selection, possibly because this is rare or possibly because the methods of finding homologous genes rely heavily on the conservation of sequence, not pattern recognition. Some flexibility is observed within the general sequence of vertebrate b-defensins with a relaxed consensus of C-X(4-8)-C-X(3-5)-C-X(9-13)-C-X(4-7)-CC being observed [29] , yet TBLASTN searches with these b-defensins do not identify ovodefensin genes. A study by Maxwell et al. [10] used hidden Markov models to identify novel mouse and human b-defensin genes and suggested that murine and human b-defensin families could be divided into two subgroups based on the strong FIG. 5 . Expression of G. gallus OvoDA1 mRNA in the magnum of juvenile chicks treated with steroids measured by RT-qPCR (n ¼ 10, mean 6 SEM). Gallus gallus OvoDA1 expression was corrected using LBR expression. Female chicks at 3 wk of age were primed with either diethylstilbestrol or vehicle and then subsequently treated with either progesterone, estrogen, or vehicle. ANOVA indicated that priming was significant at P , 0.001; steroid treatment at P , 0.001. Significance between primed state within treatment is indicated, P , 0.001 (***), and significance between treatments regardless of primed state is between the brackets, P , 0.001 (***).
WHENHAM ET AL. sequence conservation of exon 1. Regions that vary in their spacing between residues, however, are within the mature peptide and are encoded for by exon 2; this exon shows substantial divergence, consistent with rapidly evolving genes under positive selection [10] . Other approaches have been developed to get around the problem in aligning large proteins where there were differences in spacing between conserved features important for protein secondary structure [30] , and these alignments appeared to have a better agreement with the accepted view of evolution than if this were not undertaken. In large proteins, this has been used to demonstrate evolution by insertion of new domains in molecules that have effects on structure, and the authors conclude that using structure is likely to be more robust than sequence when molecules cannot be unambiguously aligned [31] . While appreciating that this is not comparable directly to the situation of a short peptide described in this article, it does offer an analogy that may be useful in terms of understanding the ways in which evolution can work on gene products. In the case of the relatively small ovodefensins, it also seems that this is the case.
This study demonstrated very different levels of activity between the ovodefensin peptides tested. However, both G. gallus and A. platyrhynchos OvoDA1 are from the same subfamily, suggesting that spacing alone does not define direct antimicrobial activity. Another possibility for differing levels of activity is charge, which varies from þ4 to þ10 within the currently identified ovodefensin members. However, charge alone is unlikely to explain all of the difference in activity, as in this study G. gallus OvoDA1 and A. platyrhynchos OvoDA1 had a very similar charge of þ7 and þ6, respectively, yet differed greatly in their activity. Additionally, an increased charge of þ10 did not result in increased activity for G. gallus OvoDB1.
RT-qPCR analysis on chicken, duck, turkey, and zebra finch representatives of the ovodefensin family demonstrate that in all cases, expression is restricted to the oviduct of the bird. However, interestingly, levels and patterns of expression within the oviduct vary between genes and species. As previously seen with G. gallus OvoDA1 [2] , G. gallus OvoDB1 was expressed more highly in the magnum of the oviduct, where the egg white is formed (Fig. 2) ; however, expression of G. gallus OvoDA1 was more than 40 times that of G. gallus OvoDB1 (Fig. 4) . In contrast to this, both the duck and the zebra finch ovodefensins were expressed most highly in the shell gland, and the turkey ovodefensins had very high levels of expression in the magnum, isthmus, and shell gland regions of the oviduct (Fig. 2) . Immunohistochemistry confirmed the expression of G. gallus OvoDB1 (Fig. 6 ) and T. guttata OvoDB1 (Fig. 7) at a peptide level in specific regions of the oviduct. Gallus gallus OvoDB1 peptide distribution was restricted to the tubular gland cells of the magnum, suggesting that it is secreted into the egg white as previously seen with G. gallus OvoDA1 [2] . In contrast, T. guttata OvoDB1 was expressed in both the tubular gland cells and the surface epithelium of the magnum, isthmus, and shell gland, suggesting that this may play a greater role in local protection of the oviduct as well as the innate defense of the egg.
Gallus gallus OvoDB1 expression in the magnum of the oviduct did not differ significantly in relation to the position of the egg in the oviduct at the time of sampling (Fig. 3) ; this was also the case for G. gallus OvoDA1 [2] . This expression profile is typical of egg proteins such as TENP [9] or ovalbumin [8] .
Both G. gallus OvoDA1 and OvoDB1 expression in the magnum was significantly higher when the hen was in-lay compared to when the oviduct was regressed (Fig. 4) , suggesting that these genes are under the control of gonadal steroids, therefore being specifically up-regulated during egg production, when steroid levels are elevated [32] . This observation was confirmed for G. gallus OvoDA1 by measurement of expression after the administration of estrogen and progesterone to juvenile hens, with estrogen producing the largest increase in expression. The increase in G. gallus OvoDA1 expression was greatest when the hens had previously been primed with an estrogenic compound, showing the synergistic activity of estrogen and progesterone expected of a gene controlled by gonadal steroids in the oviduct [21, 33] . We cannot conclude if this is a direct effect of steroids on the promoter or an indirect effect, and indeed no classical estrogen response elements were observed in the proximal promoter. 
OVIDUCT OVODEFENSIN EVOLUTION
In support of an egg defense role, G. gallus OvoDA1 was previously shown by Gong et al. [2] to be antimicrobial against a strain of E. coli, an observation that was confirmed in another three strains of E. coli by Hervé et al. [7] . The data outlined in this study also demonstrated antimicrobial activity of G. gallus OvoDA1 against laboratory-adapted and pathogenic E. coli (Fig. 8A) and, in agreement with the former publication [7] , found no activity against Salmonella serovars Enteritidis and Typhimurium. However, this study did demonstrate antimicrobial activity of G. gallus OvoDA1 against S. aureus (Fig.  8B) . Although it had been previously documented that G. gallus OvoDA1 did not possess antimicrobial activity against S. aureus [7] , both the method (solid vs. liquid phase) used to measure antimicrobial activity and the strain of S. aureus differ. This is the first time activity has been recorded for a Grampositive organism with an ovodefensin and indeed for an organism other than E. coli, demonstrating the need for more in-depth analysis of the spectrum of activity of the ovodefensins.
For the first time, this study examined the antimicrobial activity of two other avian members of the ovodefensin family: G. gallus OvoDB1 and A. platyrhynchos OvoDA1. Gallus gallus OvoDB1 represents a member of the subfamily B cysteine sequence motif (C-X3-C-X3-C-X11-C-X4-CC), whereas A. platyrhynchos OvoDA1 contains the same subfamily A cysteine sequence motif as G. gallus OvoDA1 (C-X5-C-X3-C-X11-C-X3-CC). Although G. gallus OvoDB1 possessed antimicrobial activity against E. coli DH5a (35% reduction in CFU/ml), it was not as potent as OvoDA1 from the same species at the same concentration (100 lM), and no activity was recorded against APEC, S. aureus, or either of the Salmonella strains tested in this study. Anas platyrhynchos OvoDA1 demonstrated good activity against E. coli DH5a (.80% reduction), yet no activity was recorded against any of the other strains used in this study. It should be noted that a study was previously carried out on duck ovodefensins that observed no antimicrobial activity [34] ; however, this study did not report on the method used to assess activity or whether the bacterial strains used were laboratory or pathogenic. We were able to observe activity for A. platyrhynchos OvoDA1 (dBPS2) only against the laboratory strain of E. coli, and therefore the strains used in the previous study would be of interest. The antimicrobial results from this study suggest that the family is as diverse in its activity as it is in sequence and raises the question of whether the sequence or perhaps spacing within the cysteine sequence motifs of these molecules affects their ability to kill microorganisms, perhaps evolving to counter the specific challenges each organism faces.
Overall, G. gallus OvoDA1 with motif C-X5-C-X3-C-X11-C-X3-CC was most active in the assay used and was therefore assessed in further detail, but neither pH nor salt significantly affected the ED50 in the range used in this study (Fig. 9A) . Overall potency of the peptide did diminish slightly at pH 6.4. The pH of egg white ranges from approximately 7.6 to 8.5 immediately after lay and becomes increasingly more alkaline (;9.6) as CO 2 is lost [35] ; this natural variation in pH may account for the apparent insensitivity of G. gallus OvoDA1 to the pH range used in this study. Although the ED50 value did not differ significantly between salt concentrations, it is clear that salt concentration did significantly affect the maximal potency of the peptide (Fig. 9B) . Salt sensitivity of classical mammalian defensins such as mouse b-defensin 1 [36] has been well documented, and it is postulated that this is a feature common to all defensin molecules [37] . Salt concentration in the egg is relatively low (;50mM) [38] , and the data presented in this article would suggest that ovodefensins are relatively unaffected by increased salt but share with defensin a sensitivity to salt concentration.
If ovodefensins behave as some classical vertebrate defensins, it is possible to speculate that both the direct ability to kill microorganisms and the ability to modulate the immune system may be dependent on the structure of the molecule. Further investigation will be required to determine whether the subfamilies possess differing antimicrobial activity related to characteristics such as intercysteine spacing, sequence, or charge because the naturally occurring peptides tested have too many factors varying between them to draw a conclusion about each factor in isolation. However, the large natural diversity within the ovodefensin family makes it an interesting group to study in order to understand which ovodefensin properties are important for function and may provide a resource for novel antimicrobials as well as aiding understanding when engineering new, more potent derivatives, something of great value as the threat of antibiotic resistance intensifies.
To conclude, the ovodefensins are avian-and reptilianspecific members of the b-defensin family. Expression of avian members has been demonstrated to be restricted to the oviduct and in the chicken is up-regulated in laying hens versus those with a regressed oviduct, suggesting that gonadal steroids control expression. This is confirmed by the increased expression of G. gallus OvoDA1 after administration of estrogen and progesterone in juveniles. Although the chicken ovodefensins show the classic signature of an egg-specific gene, the pattern across the range of species examined is more of an oviduct-specific family. This, coupled with the antimicrobial activity demonstrated in this study and others, suggests that ovodefensins have specifically evolved for a role in egg defense as a component of the egg's innate chemical defense; however, they may also contribute to maintaining sterility in the oviduct through local tissue activity. There is a large diversity within the ovodefensin family, with six motifs relating to spacing of the conserved cysteines discovered so far. This suggests that evolution is acting not only on amino acid sequence but also on spacing of the molecule. This novel finding offers an additional avenue of investigation for the design of new antimicrobial compounds.
